BSX · Earnings call · 2026Q3T · Full report

Guidance / Outlook

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 47 · Surprise 32 · In source text

Boston Scientific expects full-year 2026 reported revenue growth of approximately 4.25%, including an estimated 50-basis-point foreign-exchange tailwind, and operational and organic growth of approximately 3.75%. Fourth-quarter reported, operational, and organic revenue are expected to decline 1%–3% year over year; adjusted EPS guidance is $0.77–$0.79 for Q4 and $3.16–$3.18 for 2026. Full-year adjusted operating margin is expected to be approximately 27.6%, the adjusted tax rate approximately 12%, and free cash flow approximately $3.6 billion. Management expects 2027 revenue and adjusted EPS growth to be challenging excluding Penumbra, with Q4 guidance serving as a reasonable baseline.

Key facts

• Boston Scientific expects FY2026 adjusted EPS of $3.16 to $3.18, growth of 3% to 4% year over year, including an approximately $0.06 foreign-exchange headwind.
• Boston Scientific expects FY2026 adjusted below-the-line expense of approximately $485 million.
• Boston Scientific expects Q4 2026 organic revenue to decline 1% to 3% and adjusted EPS to be $0.77 to $0.79.
• Full-year 2026 organic revenue growth guidance is 4%, with adjusted EPS of $3.16 to $3.18.
• Boston Scientific expects FY2026 reported revenue growth of approximately 4.25%, and operational and organic growth of approximately 3.75% excluding an approximately 50-basis-point foreign-exchange tailwind.
• Boston Scientific expects Q4 2026 reported, operational, and organic revenue declines in a range of 3% to 1% year over year, with no foreign-exchange impact.
• Boston Scientific expects Q4 2026 adjusted EPS of $0.77 to $0.79.
• Boston Scientific expects its WAMGR to be approximately 7% currently and around 7% to 8% over the next three years.

Impact estimates